https://techpapersworld.com/wp-content/uploads/2022/05/Valneva-Receives-Notice-of-European-Commissions-Intent-1280x720.jpg

Valneva SE, a specialty vaccine company, today announced that it has received a notice from the European Commission (“EC”) of intent to terminate the advance purchase agreement (“APA”) for Valneva’s inactivated whole-virus COVID-19 vaccine candidate VLA2001. The APA provides the EC with a right to terminate the APA if VLA2001 had not received a marketing authorization from the European Medicines Agency (“EMA”) by April 30, 2022. Based on the terms of the APA, Valneva has 30...

https://techpapersworld.com/wp-content/uploads/2022/05/Poxel-Announces-Notice-of-Its-Annual.jpg

POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces the publication of the meeting notice for the Annual General Meeting, which will be held on June 21st, 2022 at 9 am CEST at Collège Hôtel, 5 Place Saint-Paul, 69005 LYON. The meeting notice, the convening brochure, the 2021 Universal Registration Document and the documents...

POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces the publication of the meeting notice for the Annual General Meeting, which will be held on June 21st, 2022 at 9 am CEST at Collège Hôtel, 5 Place Saint-Paul, 69005 LYON. The meeting notice, the convening brochure, the 2021 Universal Registration Document and the documents...

https://techpapersworld.com/wp-content/uploads/2022/05/Bone-Therapeutics-enters-into-exclusive-reverse-merger-1280x720.jpg

BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces it has entered into a non-binding term sheet and exclusive discussions for a period of three months with the shareholders of Medsenic, a privately held, clinical stage biopharmaceutical company incorporated in France and specialized in the development of optimized formulations of arsenic salts and their application in inflammatory conditions and other potential new indications....

https://techpapersworld.com/wp-content/uploads/2022/05/eureKARE-supports-eureKING-in-EUR-150-million-listing-of-the-1280x720.jpg

eureKARE (“the Company”), a pioneering company focused on financing and building next generation biotechnology companies in the disruptive fields of synthetic biology and the microbiome, today announces the successful IPO on Euronext Paris (Professional Segment) of eureKING, the first European SPAC1 in healthcare dedicated to biomanufacturing that has been co-founded by eureKARE. As founders of eureKING, eureKARE and its CEO Rodolphe Besserve bring biopharma expertise, combining novel industry monitoring and analysis with a strong track record...

https://techpapersworld.com/wp-content/uploads/2022/05/Global-Biosimulation-Market-to-Experience-Significant-Growth-1280x720.jpg

As per the report published by Market Research Place, the global biosimulation market is expected to grow from USD 2023.05 million in 2021 to USD 6,111.29 million by 2030, at a CAGR of 13.07% during the forecast period 2022-2030. Biosimulation is a web framework that provides basic user interface components common to many simulators, such as a textual model editor with syntax highlighting and a plot to display the results of time course simulation. Biosimulation assists in...

https://techpapersworld.com/wp-content/uploads/2022/05/Sirnaomics-to-Present-Latest-Developments-on-1280x720.jpg

Sirnaomics Ltd. (“Sirnaomics”, stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it will present the latest developments on its GalNAc-Liver-Targeting platforms and a progress report on its GalAhead™ technologies and programs at the TIDES USA 2022 Conference. TIDES 2022 is taking place May 9-12, 2022 at the Hynes Convention Center in Boston. Oral Presentation Details Presentation Title: mxRNA™: Miniaturized RNAi Triggers Composed of Single Oligonucleotides Presentation Segment: Oligonucleotide Discovery, Preclinical and Clinical...